What are acquired IPR&D and development milestone charges?

These charges relate to the costs associated with acquiring in-process research and development projects and achieving specific development milestones in collaborations, licensing agreements, and other asset acquisitions. They represent costs incurred when Lilly acquires or advances research and development assets.

Why is Lilly disclosing these charges in an 8-K filing?

While these charges may not be predictable and are not typically forecasted by Lilly, the company is providing an estimate of their impact on its third-quarter financial results to keep investors informed about significant expected financial events. The 8-K filing is used to report material events that are not otherwise covered in its regular periodic filings.

How significant is this $0.06 per share charge to Lilly's earnings?

The impact of $0.06 per share represents a relatively small portion of Lilly's overall earnings. Investors should consider this alongside the company's total projected earnings for the quarter to understand its relative significance. Lilly's specific earnings guidance for Q3 2022 would provide further context.

Where can I find the final Q3 2022 financial results?

The final results will be disclosed in Lilly's subsequent quarterly report on Form 10-Q, which will be filed after the financial statement closing procedures are completed and reviewed.

LLY 8-K SEC Disclosure — Oct 12, 2022

Summary

Eli Lilly and Company (LLY) has filed an 8-K report for the event date of October 11, 2022, to disclose estimated charges for acquired In-Process Research and Development (IPR&D) and development milestones for the third quarter of 2022. The company anticipates these charges to be approximately $62.4 million on a pre-tax basis, which is expected to result in a charge of $0.06 per share for both GAAP and non-GAAP earnings. These figures are preliminary and subject to finalization of financial closing procedures, with no assurance that actual results will not differ.

Key Highlights

1Estimated Q3 2022 acquired IPR&D and development milestone charges of approximately $62.4 million (pre-tax).
2These charges are expected to impact both GAAP and non-GAAP EPS by $0.06 per share.
3The company notes that these are preliminary estimates and actual results may vary.
4Lilly does not typically forecast these types of charges due to their inherent uncertainty.
5The filing also serves as a reminder for investors to monitor Lilly's website for material, non-public information and other disclosures, including social media channels.

ELI LILLY & Co 8-K Report, Corporate Update (Oct 12, 2022)

Summary

Key Highlights

Frequently Asked Questions